Abstract
Figure S3. RGS5+MYL9+ CAFs Promote EGFR-TKI-Induced DTP. (A-B) ATeam biosensor analysis demonstrates maintained cellular viability (YFP/CFP ratio) in HCC827 (A) and PC9 (B) cells co-cultured with RGS5+MYL9+ CAFs during 2 μM Osimertinib treatment. (C-D) Immunofluorescence staining reveals elevated stemness markers (CD44/CD133) in HCC827 cells protected by RGS5+MYL9+ CAFs under Osimertinib treatment. (E) Western blot shows RGS5+MYL9+ CAF-induced epithelial-mesenchymal transition (EMT) marker expression in Osimertinib treated HCC827 cells. (F) Cell cycle analysis demonstrates RGS5+MYL9+ CAFs-mediated G0/G1 arrest in osimertinib-treated HCC827 and PC9 cells. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data represent mean ± SD (*P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with Dunnett's test; ns=not significant)